Resilience Turns to Harvard for Biologics Manufacturing Tech, Inks 5-Year R&D Pact (MedCity News)

Resilience Turns to Harvard for Biologics Manufacturing Tech, Inks 5-Year R&D Pact

Resilience, a company developing technologies that overcome the challenges of manufacturing complex biological medicines, is turning to Harvard University to find some of those new solutions. Under a five-year agreement, Resilience will fund R&D of new manufacturing technologies based on discoveries from the university’s labs.

Resilience has committed $30 million to the partnership. The research will include biologic drugs, vaccines, nucleic acids, and cell and gene therapies. The partners said that these Harvard innovations may progress further in the hands of new companies formed by Resilience.

Resilience recently acquired UF startup and UF Innovate | Accelerate graduate Ology Bioservices, a Sid Martin Biotech former resident company.

Learn more about Resilience Turns to Harvard for Biologics Manufacturing Tech, Inks 5-Year R&D Pact.
X